查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球外泌体研究市场（按产品、适应症、应用和製造服务）- 预测至 2030 年
市场调查报告书
商品编码
1747197

全球外泌体研究市场（按产品、适应症、应用和製造服务）- 预测至 2030 年

Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 325 Pages | 订单完成后即时交付

价格

全球外泌体研究市场规模预计将从2025年的2.144亿美元增加到2030年的4.806亿美元，预测期间的复合年增长率为17.5%。市场扩张的主要驱动力是癌症、神经退化性疾病和心血管疾病（CVD）等慢性疾病盛行率的上升。这一趋势凸显了对新型诊断和治疗策略的迫切需求。外泌体因其潜在的生物标记特性和促进标靶治疗治疗的能力，在满足日益增长的先进疾病诊断和治疗方法需求方面具有独特的优势。

研究范围
调查年份 2024-2030
基准年 2024
预测期 2024-2030
单元 100万美元
部分 产品、用途、製造服务、最终用户、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

“预计在预测期内，套件和试剂部分将以最高的复合年增长率增长。”

随着学术机构、生物技术公司和诊断开发人员深入研究外泌体在疾病诊断和治疗性介入中的多方面作用，对标准化、易于使用的套件和试剂的需求显着增加。这些专用工具在简化和加快与外泌体分离、精製、标记和下游分析相关的工作流程方面发挥关键作用。外泌体是由细胞分泌的奈米大小的囊泡，已成为各种疾病的重要生物标记物，需要精确的处理和分析。市售套件提供的标准化有助于研究人员一致、可靠地执行这些任务，这对于转化研究和临床前开发都至关重要。可重复性在科学研究中尤其重要，使用经过认证的套件可确保一致的通讯协定，最大限度地减少变异性并提高整体研究成果。这种可靠性在生物标记发现和液态切片研究中尤其重要，在这些研究中，准确的生物标记识别对于疾病的早期发现和监测至关重要。随着人们对外泌体诊断技术的兴趣日益浓厚，尤其是在肿瘤学领域，用于检测癌症以及阿兹海默症和帕金森氏症等神经退化性疾病，越来越多的实验室选择即用型试剂系统。这些系统有助于样品製备、RNA 和 DNA 萃取以及全面的货物分析，有助于各种下游分子应用。这些标准化工具的整合不仅简化了研究方法，还提高了数据质量，最终促进了外泌体在临床环境中的研究进展。随着诊断技术的不断发展，此类可靠且高效的套件的作用将更加突出，为个人化医疗和标靶治疗的突破铺平道路。

“预计2025年至2030年间，北美将在全球外泌体研究市场中以最高的复合年增长率增长。”

北美在全球外泌体研究市场保持主导地位，这主要得益于大量的政府投入和支持机制。美国国立卫生研究院 (NIH) 等领先机构至关重要，它们为生物医学研究，尤其是以外泌体为中心的计划提供了大量资金。这些资金支持使研究人员能够探索外泌体在诊断和治疗领域的新应用。

本报告对全球外泌体研究市场进行了深入分析，包括关键驱动因素和限制因素、竞争格局和未来趋势。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 主要发现

  • 外泌体研究市场概览
  • 北美外泌体研究市场（按应用和国家划分）
  • 外泌体研究市场：地理成长机会

第五章市场概述

  • 介绍
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 任务
  • 影响客户业务的趋势/中断
  • 定价分析
    • 主要企业外泌体研究产品参考价格（2024年）
    • 外泌体研究产品价格指数（按地区）（2024年）
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 技术分析
    • 主要技术
    • 互补技术
    • 相关技术
  • 专利分析
    • 专利申请数量：依文献类型划分（2014 年至 2024 年）
    • 关键专利清单（2023-2024）
  • 大型会议和活动（2025-2026年）
  • 监管分析
    • 监管机构、政府机构和其他组织
    • 法规结构
  • 波特五力分析
  • 主要相关利益者和采购标准
  • 投资金筹措场景
  • 贸易数据分析
    • HS编码3822进口资料（2020-2024年）
    • HS编码3822出口资料（2020-2024年）
  • 人工智慧/生成式人工智慧对外泌体研究市场的影响
  • 2025年美国关税对外泌体研究市场的影响
    • 介绍
    • 主要关税税率
    • 价格影响分析
    • 对国家的影响
    • 对终端产业的影响

第六章 外泌体研究市场：依产品

  • 介绍
  • 套件和试剂
    • 抗体
    • 分离、精製和定量试剂套件和试剂
    • 其他套件和试剂
  • 装置
  • 服务

第七章 外泌体研究市场（按适应症）

  • 介绍
  • 癌症
    • 肺癌
    • 乳癌
    • 摄护腺癌
    • 大肠直肠癌
    • 其他癌症
  • 神经退化性疾病
  • 心血管疾病
  • 感染疾病
  • 其他适应症

第八章 外泌体研究市场：依应用

  • 介绍
  • 生物标誌物
  • 疫苗研发
  • 组织再生
  • 其他用途

第九章 外泌体研究市场（依製造服务）

  • 介绍
  • 干细胞来源的外泌体的产生
  • 树突细胞来源的外泌体的产生
  • 其他製造服务

第 10 章 外泌体研究市场（依最终使用者）

  • 介绍
  • 学术和研究机构
  • 製药和生物技术公司
  • 医院及临床检测机构

第 11 章 外泌体研究市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济分析
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 亚太宏观经济分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济分析
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲
    • 中东和非洲的宏观经济分析
    • 海湾合作委员会国家
    • 其他中东和非洲地区

第十二章竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 收益分析（2020-2024）
  • 市场占有率分析（2024年）
  • 企业评估矩阵：主要企业（2024年）
  • 公司评估矩阵：Start-Ups/中小企业（2024 年）
  • 公司估值和财务指标
    • 财务指标
    • 公司评估
  • 品牌/产品比较
  • 竞争场景

第十三章 公司简介

  • 主要企业
    • THERMO FISHER SCIENTIFIC INC.
    • QIAGEN
    • LONZA
    • DANAHER
    • BIO-TECHNE
    • SYSTEM BIOSCIENCES, LLC
    • AMSBIO
    • ROOSTERBIO, INC.
    • MILTENYI BIOTEC
    • NORGEN BIOTEK CORP.
    • AETHLON MEDICAL, INC.
    • CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.
    • SPECTRIS
    • NANOFCM, INC.
    • IZON SCIENCE LIMITED
    • CAPRICOR THERAPEUTICS, INC.
  • 其他公司
    • ANJARIUM BIOSCIENCES AG
    • CILOA
    • INNOVAPREP
    • ILIAS BIOLOGICS INC.
    • UNCHAINED LABS
    • RION INC.
    • CELL GUIDANCE SYSTEM LLC
    • INOVIQ
    • NX PHARMAGEN
    • EXOPHARM
    • EVERZOM
    • NANOSOMIX
    • CREATIVE BIOLABS

第十四章 附录

Product Code: BT 6939

The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period. The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD million)
SegmentsOfferings, Application, Manufacturing Service, End User, Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa

"The kits & reagents segment is expected to grow at the highest CAGR during the study period."

As academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and analysis. The standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and monitoring. With the growing interest in exosome-based diagnostics-especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer's and Parkinson's-laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted therapies.

"North America is expected to grow at the highest CAGR in the global exosome research market from 2025 to 2030."

North America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple University. Their investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays. Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America's status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research sector.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side-70% and Demand Side-30%
  • By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
  • By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), Danaher Corporation (US), Capricor Therapeutics(US), Lonza (Switzerland), QIAGEN (Germany), Creative Medical Technologies Holdings, Inc. (US), System Biosciences, LLC (US), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), Creative Biolabs (US), Nanofcm (UK), Izon Science (UK), and Malvern Panalytical (UK).

Research Coverage:

This research report categorizes the exosome research market by offering [kits & reagents (antibodies, isolation, purification, quantitation kits, reagents, and other kits & reagents), instruments, and services], indication [cancer indication (lung cancer, breast cancer, prostate cancer, colorectal cancer, other cancers), neurodegenerative diseases, cardiovascular diseases, infectious diseases, and other indications], by application [biomarkers, vaccine development, tissue regeneration, and other applications], by manufacturing services [stem cell-derived exosome manufacturing services, dendritic cell-derived exosome manufacturing services, and other manufacturing services] by end user [academic & research institutes, pharmaceutical & biotechnological companies, and hospitals & clinical laboratories] and by region [North America, Europe, Asia Pacific, Latin America, Middle East & Africa].

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the exosome research market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the Exosome Research market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading).
  • Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market.
  • Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Objectives of secondary research
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries
      • 2.1.2.2 Key objective of primary research
  • 2.2 MARKET ESTIMATION
    • 2.2.1 GLOBAL MARKET ESTIMATION
      • 2.2.1.1 Company revenue analysis (bottom-up approach)
      • 2.2.1.2 Revenue share analysis of Thermo Fisher Scientific Inc.
      • 2.2.1.3 MnM repository analysis
      • 2.2.1.4 Primary interviews
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 EXOSOME RESEARCH MARKET OVERVIEW
  • 4.2 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION AND COUNTRY
  • 4.3 EXOSOME RESEARCH MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing investment in pharmaceutical and life sciences R&D
      • 5.2.1.2 Rising focus on development of cancer therapeutics and diagnostics
      • 5.2.1.3 Growing interest in exosome-based procedures
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Technical complexity of exosome isolation and characterization
      • 5.2.2.2 Regulatory complications and uncertainty in exosome research
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High investments in emerging economies
      • 5.2.3.2 Growing interest in exosome-based therapeutics
      • 5.2.3.3 Rising demand for personalized medicines
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of standard protocols for exosome manufacturing and development
      • 5.2.4.2 Limited understanding of cargo loading capacity
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY KEY PLAYER, 2024
    • 5.4.2 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION, 2024
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Ultracentrifugation
      • 5.8.1.2 Nanoparticle tracking analysis (NTA)
    • 5.8.2 COMPLIMENTARY TECHNOLOGIES
      • 5.8.2.1 Microfluidics
      • 5.8.2.2 Western blotting/ELISA
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Next-generation sequencing
      • 5.8.3.2 Mass spectrometry
  • 5.9 PATENT ANALYSIS
    • 5.9.1 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
    • 5.9.2 LIST OF KEY PATENTS, 2023-2024
  • 5.10 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.2 REGULATORY FRAMEWORK
      • 5.11.2.1 North America
        • 5.11.2.1.1 US
        • 5.11.2.1.2 Canada
      • 5.11.2.2 Europe
        • 5.11.2.2.1 Germany
        • 5.11.2.2.2 France
        • 5.11.2.2.3 UK
      • 5.11.2.3 Asia Pacific
        • 5.11.2.3.1 China
        • 5.11.2.3.2 Japan
        • 5.11.2.3.3 India
      • 5.11.2.4 Rest of the World
        • 5.11.2.4.1 Brazil
        • 5.11.2.4.2 Argentina
        • 5.11.2.4.3 Saudi Arabia
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 THREAT OF NEW ENTRANTS
    • 5.12.2 THREAT OF SUBSTITUTES
    • 5.12.3 BARGAINING POWER OF SUPPLIERS
    • 5.12.4 BARGAINING POWER OF BUYERS
    • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 KEY BUYING CRITERIA
  • 5.14 INVESTMENT & FUNDING SCENARIO
  • 5.15 TRADE DATA ANALYSIS
    • 5.15.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
    • 5.15.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
  • 5.16 IMPACT OF AI/GEN AI ON EXOSOME RESEARCH MARKET
  • 5.17 IMPACT OF 2025 US TARIFF ON EXOSOME RESEARCH MARKET
    • 5.17.1 INTRODUCTION
    • 5.17.2 KEY TARIFF RATES
    • 5.17.3 PRICE IMPACT ANALYSIS
    • 5.17.4 IMPACTS ON COUNTRY/REGION
      • 5.17.4.1 North America
        • 5.17.4.1.1 US
      • 5.17.4.2 Europe
      • 5.17.4.3 Asia Pacific
    • 5.17.5 IMPACT ON END-USE INDUSTRIES
      • 5.17.5.1 Academic & research institutes
      • 5.17.5.2 Pharmaceutical & biotechnology companies
      • 5.17.5.3 Hospitals & clinical laboratories

6 EXOSOME RESEARCH MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 KITS & REAGENTS
    • 6.2.1 ANTIBODIES
      • 6.2.1.1 High demand for exosome-based markers for disease detection to propel market growth
    • 6.2.2 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS
      • 6.2.2.1 Availability of rapid and easy-to-use kits & reagents to ensure sustained demand
    • 6.2.3 OTHER KITS & REAGENTS
  • 6.3 INSTRUMENTS
    • 6.3.1 DEMAND FOR SCALABLE EXOSOME DEVELOPMENT THROUGH HIGH-THROUGHPUT SYSTEMS TO DRIVE GROWTH
  • 6.4 SERVICES
    • 6.4.1 LACK OF IN-HOUSE RESOURCES TO SUPPORT MARKET GROWTH

7 EXOSOME RESEARCH MARKET, BY INDICATION

  • 7.1 INTRODUCTION
  • 7.2 CANCER
    • 7.2.1 LUNG CANCER
      • 7.2.1.1 Increasing demand for advanced diagnostics for lung cancer to propel market growth
    • 7.2.2 BREAST CANCER
      • 7.2.2.1 Increased awareness and focus on better non-invasive diagnosis to aid market growth
    • 7.2.3 PROSTATE CANCER
      • 7.2.3.1 Effectiveness of liquid biopsy in detecting prostate cancer before surgery to support market growth
    • 7.2.4 COLORECTAL CANCER
      • 7.2.4.1 Rising focus on exosome-based research on tumor initiation, progression, chemoresistance, and metastasis to drive market
    • 7.2.5 OTHER CANCERS
  • 7.3 NEURODEGENERATIVE DISEASES
    • 7.3.1 INCREASED APPLICATION OF SALIVARY EXOSOMAL CARGO CONTENT IN DISEASE TREATMENT TO PROPEL MARKET GROWTH
  • 7.4 CARDIOVASCULAR DISEASES
    • 7.4.1 GREATER RESEARCH FOCUS ON EXTRACELLULAR VESICLES TO AUGMENT MARKET GROWTH
  • 7.5 INFECTIOUS DISEASES
    • 7.5.1 POTENTIAL FOR EXOSOMES IN DEVELOPING NOVEL INFECTIOUS DISEASE TREATMENTS TO AID ADOPTION
  • 7.6 OTHER INDICATIONS

8 EXOSOME RESEARCH MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 BIOMARKERS
    • 8.2.1 ABILITY TO MODULATE CELL SIGNALING AND REDUCE NEUROINFLAMMATION TO DRIVE ADOPTION
  • 8.3 VACCINE DEVELOPMENT
    • 8.3.1 NEED FOR COMBATING INFECTIOUS DISEASES TO SPUR ADOPTION OF EXOSOME-BASED VACCINES
  • 8.4 TISSUE REGENERATION
    • 8.4.1 MINIMAL SIDE EFFECTS AND HIGH EFFICACY OF EXOSOMES IN TISSUE REGENERATION TO SUPPORT ADOPTION
  • 8.5 OTHER APPLICATIONS

9 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE

  • 9.1 INTRODUCTION
  • 9.2 STEM CELL-DERIVED EXOSOME MANUFACTURING
    • 9.2.1 INCREASE IN DEMAND FOR MESENCHYMAL STEM CELLS-BASED EXOSOMES IN THERAPEUTICS TO AUGMENT MARKET GROWTH
  • 9.3 DENDRITIC CELL-DERIVED EXOSOME MANUFACTURING
    • 9.3.1 SIGNIFICANT DEVELOPMENTS IN DENDRITIC CELL-BASED EXOSOME IMMUNOTHERAPY TO DRIVE MARKET
  • 9.4 OTHER MANUFACTURING SERVICES

10 EXOSOME RESEARCH MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 ACADEMIC & RESEARCH INSTITUTES
    • 10.2.1 INCREASING NUMBER OF CANCER AND STEM CELL RESEARCH PROJECTS GLOBALLY TO AUGMENT MARKET GROWTH
  • 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.3.1 HIGH INVESTMENTS AND RAPID INNOVATIONS IN EXOSOME-BASED DIAGNOSTICS TO AID MARKET GROWTH
  • 10.4 HOSPITALS & CLINICAL TESTING LABORATORIES
    • 10.4.1 RISING ADOPTION OF EXOSOME-BASED ONCOLOGY RESEARCH SOLUTIONS TO PROPEL MARKET GROWTH

11 EXOSOME RESEARCH MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 US to dominate North American exosome research market during study period
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing funding for genome-based medical treatments to support market growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Advanced biotechnology sector and developed research facilities to favor market growth
    • 11.3.3 UK
      • 11.3.3.1 Favorable R&D initiatives and advanced life science industry to drive market
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing collaborations between biotechnology firms and research institutes to propel market growth
    • 11.3.5 ITALY
      • 11.3.5.1 Favorable government policies to propel growth of exosome research
    • 11.3.6 SPAIN
      • 11.3.6.1 Increased focus on pharmaceutical R&D to aid market growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Favorable government initiatives for development of biotechnology industry to drive market
    • 11.4.3 JAPAN
      • 11.4.3.1 High prevalence of cancer and increased healthcare expenditure to aid market growth
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing number of institutional alliances and growing focus on clinical innovation to support market growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Substantial government funding and innovative applications in regenerative medicines to augment market growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Favorable government initiatives and routine clinical trials to support market growth
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Increased government investments in pharmaceutical R&D to drive market
    • 11.5.3 MEXICO
      • 11.5.3.1 Advancements in regenerative medicines and exosome-based therapies to support market growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Strong focus on local pharmaceutical R&D to fuel market growth
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EXOSOME RESEARCH MARKET
  • 12.3 REVENUE ANALYSIS, 2020-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Offering footprint
      • 12.5.5.4 Indication footprint
      • 12.5.5.5 Application footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.6.5.1 Detailed list of key startups/SMEs
      • 12.6.5.2 Competitive benchmarking of key startups/SME players, by offering and region
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 THERMO FISHER SCIENTIFIC INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products/Services/Solutions offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Deals
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 QIAGEN
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products/Services/Solutions offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 LONZA
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products/Services/Solutions offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Deals
        • 13.1.3.3.2 Expansions
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 DANAHER
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products/Services/Solutions offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product launches
        • 13.1.4.3.2 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 BIO-TECHNE
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products/Services/Solutions offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key strengths
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 SYSTEM BIOSCIENCES, LLC
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products/Services/Solutions offered
    • 13.1.7 AMSBIO
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products/Services/Solutions offered
    • 13.1.8 ROOSTERBIO, INC.
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products/Services/Solutions offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Deals
    • 13.1.9 MILTENYI BIOTEC
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products/Services/Solutions offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches
    • 13.1.10 NORGEN BIOTEK CORP.
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products/Services/Solutions offered
    • 13.1.11 AETHLON MEDICAL, INC.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products/Services/Solutions offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product approvals
    • 13.1.12 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products/Services/Solutions offered
    • 13.1.13 SPECTRIS
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products/Services/Solutions offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Product launches
        • 13.1.13.3.2 Deals
    • 13.1.14 NANOFCM, INC.
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products/Services/Solutions offered
    • 13.1.15 IZON SCIENCE LIMITED
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products/Services/Solutions offered
    • 13.1.16 CAPRICOR THERAPEUTICS, INC.
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products/Services/Solutions offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 ANJARIUM BIOSCIENCES AG
    • 13.2.2 CILOA
    • 13.2.3 INNOVAPREP
    • 13.2.4 ILIAS BIOLOGICS INC.
    • 13.2.5 UNCHAINED LABS
    • 13.2.6 RION INC.
    • 13.2.7 CELL GUIDANCE SYSTEM LLC
    • 13.2.8 INOVIQ
    • 13.2.9 NX PHARMAGEN
    • 13.2.10 EXOPHARM
    • 13.2.11 EVERZOM
    • 13.2.12 NANOSOMIX
    • 13.2.13 CREATIVE BIOLABS

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 EXOSOME RESEARCH MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 EXOSOME RESEARCH MARKET: RISK ANALYSIS
  • TABLE 4 EXOSOME RESEARCH MARKET: IMPACT ANALYSIS
  • TABLE 5 GLOBAL CANCER INCIDENCE, BY REGION, 2022 VS. 2025
  • TABLE 6 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY KEY PLAYER, 2024
  • TABLE 7 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION, 2024 (USD)
  • TABLE 8 EXOSOME RESEARCH MARKET: ROLE IN ECOSYSTEM
  • TABLE 9 EXOSOME RESEARCH MARKET: NUMBER OF PATENTS FILED, 2014-2024
  • TABLE 10 EXOSOME RESEARCH MARKET: DETAILED ANALYSIS OF KEY PATENTS, 2023-2024
  • TABLE 11 EXOSOME RESEARCH MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EXOSOME RESEARCH MARKET: PORTER'S FIVE FORCES
  • TABLE 17 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • TABLE 18 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 19 IMPORT DATA FOR HS CODE 3822, 2020-2024 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 3822, 2020-2024 (USD THOUSAND)
  • TABLE 21 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 EXOSOME RESEARCH PRODUCTS-RELATED TARIFF REVISION
  • TABLE 23 EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 24 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 25 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 26 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 LATIN AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 MIDDLE EAST & AFRICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 30 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 31 ANTIBODIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 32 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 37 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 38 NORTH AMERICA: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 EUROPE: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 LATIN AMERICA: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 MIDDLE EAST & AFRICA: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 43 OTHER KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 49 EXOSOME RESEARCH INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 NORTH AMERICA: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 EUROPE: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 LATIN AMERICA: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 MIDDLE EAST & AFRICA: EXOSOME RESEARCH INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 55 EXOSOME RESEARCH SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 NORTH AMERICA: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 EUROPE: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 LATIN AMERICA: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 MIDDLE EAST & AFRICA: EXOSOME RESEARCH SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 61 EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 62 EXOSOME RESEARCH MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 EUROPE: EXOSOME RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 68 EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 69 LUNG CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 EUROPE: LUNG CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: LUNG CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 75 BREAST CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 76 NORTH AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 EUROPE: BREAST CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: BREAST CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 LATIN AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 MIDDLE EAST & AFRICA: BREAST CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 PROSTATE CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: PROSTATE CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 EUROPE: PROSTATE CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: PROSTATE CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 LATIN AMERICA: PROSTATE CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA: PROSTATE CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 87 COLORECTAL CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 EUROPE: COLORECTAL CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: COLORECTAL CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 LATIN AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 MIDDLE EAST & AFRICA: COLORECTAL CANCER MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 93 OTHER CANCERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 EUROPE: OTHER CANCERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: OTHER CANCERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 LATIN AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 MIDDLE EAST & AFRICA: OTHER CANCERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 99 EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 100 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 101 EUROPE: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 105 EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 106 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030(USD MILLION)
  • TABLE 107 EUROPE: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030(USD MILLION)
  • TABLE 108 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030(USD MILLION)
  • TABLE 109 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030(USD MILLION))
  • TABLE 110 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030(USD MILLION)
  • TABLE 111 EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 112 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 EUROPE: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 115 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 117 EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 EUROPE: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 123 EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 124 EXOSOME RESEARCH MARKET FOR BIOMARKERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 EUROPE: EXOSOME RESEARCH MARKET FOR BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR BIOMARKERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 MIDDLE EAST & AFRICA & AFRICA: EXOSOME RESEARCH MARKET FOR BIOMARKERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 130 EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 EUROPE: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 136 EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 EUROPE: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 142 EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 144 EUROPE: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 148 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE, 2023-2030 (USD MILLION)
  • TABLE 149 EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 150 EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 151 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 EUROPE: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 156 EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 157 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 158 EUROPE: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 162 EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 163 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 EUROPE: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 166 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 168 EXOSOME RESEARCH MARKET: KEYWORD RELEVANCE, TREND, AND PRIMARY FOCUS, 2015-2024
  • TABLE 169 EXOSOME RESEARCH MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 170 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 171 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 172 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 173 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 174 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 175 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 178 US: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 179 US: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 180 US: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 181 US: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 182 US: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 183 US: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 184 CANADA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 185 CANADA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 186 CANADA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 187 CANADA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 188 CANADA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 189 CANADA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 190 EUROPE: KEY MACROINDICATORS
  • TABLE 191 EUROPE: EXOSOME RESEARCH MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 192 EUROPE: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 193 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 194 EUROPE: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 195 EUROPE: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 196 EUROPE: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 197 EUROPE: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 198 GERMANY: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 199 GERMANY: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 200 GERMANY: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 201 GERMANY: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 202 GERMANY: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 203 GERMANY: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 204 UK: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 205 UK: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 206 UK: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 207 UK: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 208 UK: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 209 UK: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 210 FRANCE: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 211 FRANCE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 212 FRANCE: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 213 FRANCE: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 214 FRANCE: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 215 FRANCE: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 216 ITALY: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 217 ITALY: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 218 ITALY: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 219 ITALY: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 220 ITALY: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 221 ITALY: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 222 SPAIN: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 223 SPAIN: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 224 SPAIN: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 225 SPAIN: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 226 SPAIN: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 227 SPAIN: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 228 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 229 REST OF EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 230 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 231 REST OF EUROPE: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 232 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 233 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 235 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 237 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 242 CHINA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 243 CHINA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 244 CHINA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 245 CHINA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 246 CHINA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 247 CHINA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 248 JAPAN: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 249 JAPAN: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 JAPAN: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 251 JAPAN: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 252 JAPAN: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 253 JAPAN: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 254 INDIA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 255 INDIA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 256 INDIA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 257 INDIA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 258 INDIA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 259 INDIA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 260 AUSTRALIA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 261 AUSTRALIA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 262 AUSTRALIA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 263 AUSTRALIA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 264 AUSTRALIA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 265 AUSTRALIA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 266 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 267 SOUTH KOREA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 268 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 269 SOUTH KOREA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 270 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 271 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 272 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 278 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 279 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 280 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 281 LATIN AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 282 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 283 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 284 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 285 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 286 BRAZIL: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 287 BRAZIL: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 BRAZIL: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 289 BRAZIL: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 290 BRAZIL: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 291 BRAZIL: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 292 MEXICO: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 293 MEXICO: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 294 MEXICO: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 295 MEXICO: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 296 MEXICO: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 297 MEXICO: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 298 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 299 REST OF LATIN AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 301 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 302 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 303 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 304 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 305 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 306 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 307 MIDDLE EAST & AFRICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 309 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 311 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 312 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 314 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 315 GCC COUNTRIES: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 316 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 317 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 318 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 319 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 321 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 322 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 323 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 324 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN EXOSOME RESEARCH MARKET, JANUARY 2022-MAY 2025
  • TABLE 325 EXOSOME RESEARCH MARKET: DEGREE OF COMPETITION
  • TABLE 326 EXOSOME RESEARCH MARKET: REGION FOOTPRINT
  • TABLE 327 EXOSOME RESEARCH MARKET: OFFERING FOOTPRINT
  • TABLE 328 EXOSOME RESEARCH MARKET: INDICATION FOOTPRINT
  • TABLE 329 EXOSOME RESEARCH MARKET: APPLICATION FOOTPRINT
  • TABLE 330 EXOSOME RESEARCH MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 331 EXOSOME RESEARCH MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SME PLAYERS, BY OFFERING AND REGION, 2024
  • TABLE 332 EXOSOME RESEARCH MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 333 EXOSOME RESEARCH MARKET: DEALS, JANUARY 2022-MAY 2025
  • TABLE 334 EXOSOME RESEARCH MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 335 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 336 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 337 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 338 QIAGEN: COMPANY OVERVIEW
  • TABLE 339 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 340 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 341 LONZA: COMPANY OVERVIEW
  • TABLE 342 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 343 LONZA: DEALS, JANUARY 2022-MAY 2025
  • TABLE 344 LONZA: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 345 DANAHER: COMPANY OVERVIEW
  • TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 347 DANAHER: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 348 DANAHER: DEALS, JANUARY 2022-MAY 2025
  • TABLE 349 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 350 BIO-TECHNE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 351 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 352 SYSTEM BIOSCIENCES, LLC: COMPANY OVERVIEW
  • TABLE 353 SYSTEM BIOSCIENCES, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 354 AMSBIO: COMPANY OVERVIEW
  • TABLE 355 AMSBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 356 ROOSTERBIO, INC.: COMPANY OVERVIEW
  • TABLE 357 ROOSTERBIO, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 358 ROOSTERBIO, INC.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 359 MILTENYI BIOTEC: COMPANY OVERVIEW
  • TABLE 360 MILTENYI BIOTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 361 MILTENYI BIOTEC: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 362 NORGEN BIOTEK CORP.: COMPANY OVERVIEW
  • TABLE 363 NORGEN BIOTEK CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 364 AETHLON MEDICAL, INC.: COMPANY OVERVIEW
  • TABLE 365 AETHLON MEDICAL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 366 AETHLON MEDICAL, INC.: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 367 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.: COMPANY OVERVIEW
  • TABLE 368 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 369 SPECTRIS: COMPANY OVERVIEW
  • TABLE 370 SPECTRIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 371 SPECTRIS: PRODUCT LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 372 SPECTRIS: DEALS, JANUARY 2022-MAY 2025
  • TABLE 373 NANOFCM, INC.: COMPANY OVERVIEW
  • TABLE 374 NANOFCM, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 375 IZON SCIENCE LIMITED: COMPANY OVERVIEW
  • TABLE 376 IZON SCIENCE LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 377 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 378 CAPRICOR THERAPEUTICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 379 ANJARIUM BIOSCIENCES AG: COMPANY OVERVIEW
  • TABLE 380 CILOA: COMPANY OVERVIEW
  • TABLE 381 INNOVAPREP: COMPANY OVERVIEW
  • TABLE 382 ILIAS BIOLOGICS INC.: COMPANY OVERVIEW
  • TABLE 383 UNCHAINED LABS: COMPANY OVERVIEW
  • TABLE 384 RION INC.: COMPANY OVERVIEW
  • TABLE 385 CELL GUIDANCE SYSTEM LLC: COMPANY OVERVIEW
  • TABLE 386 INOVIQ: COMPANY OVERVIEW
  • TABLE 387 NX PHARMAGEN: COMPANY OVERVIEW
  • TABLE 388 EXOPHARM: COMPANY OVERVIEW
  • TABLE 389 EVERZOM: COMPANY OVERVIEW
  • TABLE 390 NANOSOMIX: COMPANY OVERVIEW
  • TABLE 391 CREATIVE BIOLABS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 EXOSOME RESEARCH MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 EXOSOME RESEARCH MARKET: YEARS CONSIDERED
  • FIGURE 3 EXOSOME RESEARCH MARKET: RESEARCH DESIGN
  • FIGURE 4 EXOSOME RESEARCH MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 EXOSOME RESEARCH MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
  • FIGURE 6 EXOSOME RESEARCH MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
  • FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC. (2024)
  • FIGURE 9 EXOSOME RESEARCH MARKET: KEY INSIGHTS FROM PRIMARIES
  • FIGURE 10 EXOSOME RESEARCH MARKET: TOP-DOWN APPROACH
  • FIGURE 11 EXOSOME RESEARCH MARKET: CAGR PROJECTIONS
  • FIGURE 12 EXOSOME RESEARCH MARKET: DATA TRIANGULATION
  • FIGURE 13 EXOSOME RESEARCH MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 EXOSOME RESEARCH MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 EXOSOME RESEARCH MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 EXOSOME RESEARCH MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 REGIONAL SNAPSHOT OF EXOSOME RESEARCH MARKET
  • FIGURE 18 HIGH DEMAND FOR PRECISION MEDICINES AND STRONG PHARMACEUTICAL R&D INFRASTRUCTURE TO DRIVE MARKET
  • FIGURE 19 US AND BIOMARKERS COMMANDED LARGEST SHARE OF NORTH AMERICAN EXOSOME RESEARCH MARKET IN 2024
  • FIGURE 20 US TO WITNESS HIGHEST CAGR FROM 2025 TO 2030
  • FIGURE 21 EXOSOME RESEARCH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 EXOSOME RESEARCH MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 23 INDICATIVE PRICE OF EXOSOME KITS & REAGENTS, BY KEY PLAYER (2024)
  • FIGURE 24 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION (2024)
  • FIGURE 25 EXOSOME RESEARCH MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 26 EXOSOME RESEARCH MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 EXOSOME RESEARCH MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 28 EXOSOME RESEARCH MARKET: TOP PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS GRANTED, JANUARY 2014-DECEMBER 2024
  • FIGURE 29 EXOSOME RESEARCH MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 30 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 31 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 32 EXOSOME RESEARCH MARKET: FUNDING AND NUMBER OF DEALS, 2020-2024
  • FIGURE 33 EXOSOME RESEARCH MARKET: IMPACT OF AI/GEN AI
  • FIGURE 34 NORTH AMERICA: EXOSOME RESEARCH MARKET SNAPSHOT
  • FIGURE 35 EUROPE: EXOSOME RESEARCH MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN EXOSOME RESEARCH MARKET, 2020-2024 (USD MILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN EXOSOME RESEARCH MARKET (2024)
  • FIGURE 38 EXOSOME RESEARCH MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 39 EXOSOME RESEARCH MARKET: COMPANY FOOTPRINT
  • FIGURE 40 EXOSOME RESEARCH MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 43 EXOSOME RESEARCH MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 45 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 46 LONZA: COMPANY SNAPSHOT
  • FIGURE 47 DANAHER: COMPANY SNAPSHOT
  • FIGURE 48 BIO-TECHNE: COMPANY SNAPSHOT
  • FIGURE 49 AETHLON MEDICAL, INC.: COMPANY SNAPSHOT
  • FIGURE 50 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.: COMPANY SNAPSHOT
  • FIGURE 51 SPECTRIS: COMPANY SNAPSHOT
  • FIGURE 52 CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT